+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance

The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance

Clinical Cancer Research 16(24): 6060-6070

Multiple developmental pathways including Notch, Hedgehog, and Wnt are active in malignant brain tumors such as medulloblastoma and glioblastoma (GBM). This raises the possibility that tumors might compensate for therapy directed against one pathway by upregulating a different one. We investigated whether brain tumors show resistance to therapies against Notch, and whether targeting multiple pathways simultaneously would kill brain tumor cells more effectively than monotherapy. We used GBM neurosphere lines to investigate the effects of a gamma-secretase inhibitor (MRK-003) on tumor growth, and chromatin immunoprecipitation to study the regulation of other genes by Notch targets. We also evaluated the effect of combined therapy with a Hedgehog inhibitor (cyclopamine) in GBM and medulloblastoma lines, and in primary human GBM cultures. GBM cells are at least partially resistant to long-term MRK-003 treatment, despite ongoing Notch pathway suppression, and show concomitant upregulation of Wnt and Hedgehog activity. The Notch target Hes1, a repressive transcription factor, bound the Gli1 first intron, and may inhibit its expression. Similar results were observed in a melanoma-derived cell line. Targeting Notch and Hedgehog simultaneously induced apoptosis, decreased cell growth, and inhibited colony-forming ability more dramatically than monotherapy. Low-passage neurospheres isolated from freshly resected human GBMs were also highly susceptible to coinhibition of the two pathways, indicating that targeting multiple developmental pathways can be more effective than monotherapy at eliminating GBM-derived cells. Notch may directly suppress Hedgehog via Hes1 mediated inhibition of Gli1 transcription, and targeting both pathways simultaneously may be more effective at eliminating GBMs cells.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 056204347

Download citation: RISBibTeXText

PMID: 21169257

DOI: 10.1158/1078-0432.ccr-10-1624

Related references

Synergism between Hedgehog-GLI and EGFR signaling in Hedgehog-responsive human medulloblastoma cells induces downregulation of canonical Hedgehog-target genes and stabilized expression of GLI1. Plos One 8(6): E65403, 2014

Menin directly represses Gli1 expression independent of canonical Hedgehog signaling. Molecular Cancer Research 11(10): 1215-1222, 2014

Sonic Hedgehog-Gli1 signaling pathway might become an effective therapeutic target in gastrointestinal neuroendocrine carcinomas. Cancer Biology and Therapy 5(11): 1530-1538, 2006

Hedgehog to Hes1: the heist of a Notch target. Cell Cycle 8(9): 1301-1302, 2009

Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. Inflammatory Bowel Diseases 17(11): 2251-2260, 2012

Sonic Hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling. Oncogene 27(10): 1489-1500, 2007

RNA editing of the GLI1 transcription factor modulates the output of Hedgehog signaling. Rna Biology 10(2): 321-333, 2013

Ikaros directly represses the notch target gene Hes1 in a leukemia T cell line: implications for CD4 regulation. Journal of Biological Chemistry 283(16): 10476-10484, 2008

Integrative genomic analyses on GLI1: positive regulation of GLI1 by Hedgehog-GLI, TGFbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. International Journal of Oncology 35(1): 187-192, 2009

Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target. Cancer Letters 370(2): 313-323, 2016

HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors. Bmc Veterinary Research 9: 130, 2015

β-arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells. Bmc Cancer 17(1): 488, 2018

Notch Signaling: A Potential Therapeutic Target in Prostate Cancer. Current Cancer Drug Targets 8(7): 566-580, 2008

Notch Signaling: A Potential Therapeutic Target for Hematologic Malignancies. Critical Reviews in Eukaryotic Gene Expression 26(3): 239-246, 2017

Notch signaling: a potential therapeutic target in prostate cancer. Current Cancer Drug Targets 8(7): 566-580, 2008